Connect before building
Use existing imaging, pharmacy, infusion, oncology, specialty, and therapy resources before creating duplicate operations.
Health-system leadership brief
A new pathway, not a duplicate department.
The opportunity is to organize capabilities that may already exist across the health system into one visible, accountable, MSCP-led model.
The opportunity
The pieces can exist without the pathway existing.
Women may enter through primary care, general gynecology, urogynecology, oncology, endocrinology, rheumatology, radiology, or an infusion center. Each service can perform its role well while the patient still experiences disconnected care.
StrongHer Care creates the connective structure: a single clinical entry point, standardized assessment, an accountable treatment plan, coordinated referrals, and longitudinal follow-up.
Design principles
A disciplined model built for integration.
Create one front door
Give patients and referring clinicians one identifiable destination for overlapping midlife concerns.
Assign clinical ownership
One program holds the longitudinal plan, closes referral loops, and knows what happens next.
Protect evidence standards
Standardize intake, risk documentation, shared decision-making, treatment monitoring, and escalation.
Start as a pilot
Test demand, workflow, staffing, outcomes, and financial performance before broader expansion.
Measure what matters
Track access, clinical process, experience, safety, system retention, and contribution margin.
Target population
Women whose needs cross more than one traditional lane.
Perimenopause and menopause symptoms
Early, premature, and surgical menopause
GSM, recurrent UTIs, and pelvic-floor symptoms
Sexual pain or dysfunction
Breast and gynecologic cancer survivorship needs
Osteopenia, osteoporosis, fragility fracture, or elevated fracture risk
Patient flow
One work queue. One assessment. The right connected services.
STEP 01Referral or identified need
STEP 02Standardized intake and triage
STEP 03Comprehensive specialty evaluation
STEP 04Individualized care and coordinated services
STEP 05Longitudinal monitoring and closed loops
Phased implementation
Begin with a coherent pilot, then grow from evidence.
Clinical focus
Menopause, GSM, pelvic health, sexual health, and cancer-survivorship consultations
Operational focus
Protected clinic template, intake, documentation, referral criteria, and core staffing
Clinical focus
Formal fracture-risk, DXA, zoledronic acid, and denosumab pathways
Operational focus
Pharmacy, authorization, laboratory, infusion, and monitoring protocols
Clinical focus
Expanded access, education, and regional referrals
Operational focus
Outreach, telehealth where appropriate, outcome reporting, and replication assessment
Required infrastructure
This program cannot be an invisible add-on to a full clinic.
Protected clinical access
A defined program session with visit lengths appropriate for comprehensive new evaluations and follow-up.
RN and referral support
Triage, education, results, medication monitoring, prior authorization, and infusion coordination.
Epic-enabled pathways
Referral orders, work queues, templates, order sets, tracking, and closed-loop communication.
Clinical guardrails
Clear scope protects patients and partners.
- The program does not replace primary care, oncology, endocrinology, rheumatology, general gynecology, or existing bone-health expertise.
- It does not duplicate infusion infrastructure when safe, available system resources can be used.
- Cancer-survivorship services focus on menopause, GSM, sexual health, and bone health, not oncologic surveillance.
- Complex metabolic bone disease is escalated to the appropriate specialist.
- Therapy is evidence-based, individualized, monitored, and documented through shared decision-making.
Pilot scorecard
Success must be visible.
Referral volume and source
New-patient access time
DXA and fracture-risk documentation
Treatment initiation and completion
On-time denosumab administration and transition planning
Patient-reported symptom improvement
Patient and referring-clinician experience
Safety, system retention, and financial performance
Initial leadership decision
Authorize the design process.
Designate an executive sponsor and convene a small, time-limited feasibility group to define the clinical, operational, financial, pharmacy, infusion, imaging, staffing, and Epic requirements for a six-month pilot.
Proposed design period: 60 to 90 days, followed by a defined go or no-go decision and pilot charter.